Fennec Pharmaceuticals Announces Jeffrey S. Hackman As New CEO And Director

Fennec Pharmaceuticals Inc., a leading specialty pharmaceutical company, has appointed Jeff Hackman as its new Chief Executive Officer and Board Director, effective around August 16, 2024. Hackman will steer Fennec's strategic initiatives, focusing on expanding the use of PEDMARK® in community oncology and among adolescents and young adults (AYA).

Jeff brings over three decades of commercial leadership experience to Fennec, having overseen the launch of more than 10 products across diverse therapeutic areas and markets. His last 12 years in oncology include roles at Sigma Tau, Baxalta, Shire, and EUSA Pharma, where he managed U.S. commercial operations and multiple product franchises, generating billions in revenue. Notably, Jeff has successfully commercialized products relevant to PEDMARK®'s target markets, including the outpatient oncology community and the adolescent and young adult (AYA) population.

Dr. Khalid Islam, Chairman of Fennec Pharmaceuticals stated, “Jeff’s appointment comes at a pivotal time for Fennec as we continue to advance PEDMARK®, the first and only therapy approved in the U.S. and Europe to reduce the risk of permanent damage from cisplatin-induced ototoxicity in pediatric cancer patients. We are confident that Jeff’s deep expertise in the commercialization of new therapies across multiple oncology indications, and extensive experience leading organizational growth and transformation, will bring tremendous value to Fennec.”

Jeffrey S. Hackman, incoming Chief Executive Officer of Fennec Pharmaceuticals mentioned, “I am excited to lead Fennec and look forward to working with management and the Board of Directors to bring this much-needed treatment to oncology patients.”

Rosty Raykov, Fennec’s CEO since 2009, will continue to serve on the Board of Directors. Khalid Islam praised Raykov's dedication, stating, “Rosty’s unwavering commitment and leadership since 2009 has been critical to Fennec in bringing a much-needed therapy to the oncology population at risk of irreversible hearing loss, which can have a profound lifelong impact on patients.”